These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31888882)

  • 1. Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers.
    Collins KS; Metzger IF; Gufford BT; Lu JB; Medeiros EB; Pratt VM; Skaar TC; Desta Z
    Drug Metab Dispos; 2020 Mar; 48(3):169-175. PubMed ID: 31888882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.
    Oswald S; Meyer zu Schwabedissen HE; Nassif A; Modess C; Desta Z; Ogburn ET; Mostertz J; Keiser M; Jia J; Hubeny A; Ulrich A; Runge D; Marinova M; Lütjohann D; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2012 Mar; 91(3):506-13. PubMed ID: 22297387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.
    Lee LS; Pham P; Flexner C
    Ann Acad Med Singap; 2012 Dec; 41(12):559-62. PubMed ID: 23303112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum bilirubin concentration in healthy adult North-Europeans is strictly controlled by the UGT1A1 TA-repeat variants.
    Kringen MK; Piehler AP; Grimholt RM; Opdal MS; Haug KB; Urdal P
    PLoS One; 2014; 9(2):e90248. PubMed ID: 24587300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
    Kwara A; Cao L; Yang H; Poethke P; Kurpewski J; Tashima KT; Mahjoub BD; Court MH; Peloquin CA
    Pharmacotherapy; 2014 Mar; 34(3):265-71. PubMed ID: 24420746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
    Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
    Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.
    Hu M; Tomlinson B
    Atherosclerosis; 2012 Aug; 223(2):427-32. PubMed ID: 22749334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of polymorphisms in four bilirubin metabolism genes with serum bilirubin in three Asian populations.
    Lin R; Wang X; Wang Y; Zhang F; Wang Y; Fu W; Yu T; Li S; Xiong M; Huang W; Jin L
    Hum Mutat; 2009 Apr; 30(4):609-15. PubMed ID: 19243019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies.
    Kobie J; Guo Z; Cho CR; Menzel K; McCrea JB; Blanchard R; Shaw PM
    J Clin Pharmacol; 2019 Sep; 59(9):1236-1243. PubMed ID: 31022310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study.
    Sun Q; Liu HP; Zheng RJ; Wang P; Liu ZB; Sha W; Xiao HP
    Clin Drug Investig; 2017 Dec; 37(12):1125-1136. PubMed ID: 28900877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.
    Ni W; Ji J; Dai Z; Papp A; Johnson AJ; Ahn S; Farley KL; Lin TS; Dalton JT; Li X; Jarjoura D; Byrd JC; Sadee W; Grever MR; Phelps MA
    PLoS One; 2010 Nov; 5(11):e13792. PubMed ID: 21072184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Factors and Delayed TSB Monitoring and Treatment as Risk Factors Associated with Severe Hyperbilirubinemia in Term Neonates Admitted for Phototherapy.
    Boo NY; Sin S; Chee SC; Mohamed M; Ahluwalia AK; Ling MM; Ong HK
    J Trop Pediatr; 2020 Dec; 66(6):569-582. PubMed ID: 32577754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population.
    Lin R; Wang Y; Wang Y; Fu W; Zhang D; Zheng H; Yu T; Wang Y; Shen M; Lei R; Wu H; Sun A; Zhang R; Wang X; Xiong M; Huang W; Jin L
    Pharmacogenet Genomics; 2009 Apr; 19(4):310-8. PubMed ID: 19238116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.
    Metzger IF; Quigg TC; Epstein N; Aregbe AO; Thong N; Callaghan JT; Flockhart DA; Nguyen AT; Stevens CK; Gupta SK; Desta Z
    Curr Ther Res Clin Exp; 2014 Dec; 76():64-9. PubMed ID: 25352936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exome-Wide Association Study Identifies New Low-Frequency and Rare UGT1A1 Coding Variants and UGT1A6 Coding Variants Influencing Serum Bilirubin in Elderly Subjects: A Strobe Compliant Article.
    Oussalah A; Bosco P; Anello G; Spada R; Guéant-Rodriguez RM; Chery C; Rouyer P; Josse T; Romano A; Elia M; Bronowicki JP; Guéant JL
    Medicine (Baltimore); 2015 Jun; 94(22):e925. PubMed ID: 26039129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case study 5. Deconvoluting hyperbilirubinemia: differentiating between hepatotoxicity and reversible inhibition of UGT1A1, MRP2, or OATP1B1 in drug development.
    Templeton I; Eichenbaum G; Sane R; Zhou J
    Methods Mol Biol; 2014; 1113():471-83. PubMed ID: 24523126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined Effects of
    Bai J; Luo L; Liu S; Liang C; Bai L; Chen Y; Zheng S; Duan Z
    Front Genet; 2019; 10():1073. PubMed ID: 31737051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide association meta-analysis for total serum bilirubin levels.
    Johnson AD; Kavousi M; Smith AV; Chen MH; Dehghan A; Aspelund T; Lin JP; van Duijn CM; Harris TB; Cupples LA; Uitterlinden AG; Launer L; Hofman A; Rivadeneira F; Stricker B; Yang Q; O'Donnell CJ; Gudnason V; Witteman JC
    Hum Mol Genet; 2009 Jul; 18(14):2700-10. PubMed ID: 19414484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Genetic Modifiers of Bilirubin Metabolism Involvement in Significant Neonatal Hyperbilirubinemia in Patients of Chinese Descent.
    Yang H; Wang Q; Zheng L; Lin M; Zheng XB; Lin F; Yang LY
    PLoS One; 2015; 10(7):e0132034. PubMed ID: 26146841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.
    Zhang W; He YJ; Gan Z; Fan L; Li Q; Wang A; Liu ZQ; Deng S; Huang YF; Xu LY; Zhou HH
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1240-4. PubMed ID: 17973861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.